arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Century Therapeutics, Inc.

IPSC

$1.91 ▼ -0.06 (-3.30%) at close

7 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Century Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $165.3M

Dividend Yield —

Revenue Growth 1556.8% ↗

Op. Margin -15.8%

ROIC -10.8% ↗

FCF / Share $-1.21 ↗

Trailing P/E —

Price / Book 1.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$109.16M

↑ +1556.8% —

Net Income Profit after all expenses

$-9.58M

↑ +92.4% —

FCF / Share Free cash flow per share

$-1.21

↑ +13.7% —

Long-Term Debt Long-term obligations

$10.39M

— 0.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	1556.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+19360%)	194.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2335%)	-57.0% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-813%)	—	—	—	—
EPS Growth YoY (%)	91.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	30.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-1.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	23.3% Good Good Year-over-year change in earnings per share Optimal: > 10%	58.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	92.4% Excellent ↑ Excellent Improving Year-over-year change in net income	7.4% Fair ↑ Fair Improving Year-over-year change in net income	-4.4% Weak ↑ Weak Improving Year-over-year change in net income	-36.6% Weak Weak Year-over-year change in net income	-78.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	13.7% Fair ↑ Fair Improving Year-over-year change in free cash flow	18.5% Good ↑ Good Improving Year-over-year change in free cash flow	-500.5% Weak ↓ Weak Declining Year-over-year change in free cash flow	93.1% Excellent Excellent Year-over-year change in free cash flow	39.4% Excellent Excellent Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	175.9% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	-15.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-205%)	—	—	—	—	—	—
Effective Tax Rate (%) (%)	0.7% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	-8.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-173%)	—	—	—	—	—	—
FCF Margin (%) (%)	-95.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	-318.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	10.93x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.13x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.40x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-10.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-86.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-80.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	44.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-7.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-39.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-40.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-21.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-50.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-6.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-140%)	-78.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-623%)	-74.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-593%)	-43.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-388%)	-24.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-261%)	50.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+236%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	—	—	—	0.03x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-94%)	0.03x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-96%)	-0.09x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-115%)	—
Interest Coverage (x)	—	—	-271.38x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-95.32x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-74.42x Weak Weak Operating income divided by interest expense Optimal: > 5x	-141.46x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-61.85M	$-58.44M	$-47.32M	$-73.87M	$-46.05M	$-17.57M	—
Debt / EBITDA (x)	—	—	—	-0.08x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.11x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.18x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$1.26	$0.08	$0.04	$0.09	—	—	—
Basic EPS, GAAP (USD)	$-0.14	$-1.61	$-2.30	$-2.27	$-2.96	$-7.16	—
Free Cash Flow per Share (USD)	$-1.21	$-1.40	$-1.72	$-0.29	$-4.14	$-6.83	—
Book Value per Share (USD)	$1.82	$1.88	$3.06	$5.50	$7.20	$-14.22	—
Tangible Book Value per Share (USD)	$1.43	$1.48	$3.06	$5.50	$7.20	$-14.22	—
Basic Weighted Avg Shares (shares)	86.56M	78.65M	59.31M	57.76M	32.39M	7.48M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$100.54M	$64.27M	$159.15M	$289.90M	$212.50M	$66.69M	—
LT Debt (USD)	—	—	—	$10.39M	$10.39M	$9.64M	—
Total Equity (USD)	$158.94M	$161.36M	$184.75M	$302.74M	$396.24M	$-106.41M	$-91.86M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$109.16M	$6.59M	$2.23M	$5.20M	—	—	—
Depreciation Expense (USD)	$13.10M	$13.30M	$13.04M	$8.44M	$3.75M	$1.40M	—
Net Income, GAAP (USD)	$-9.58M	$-126.57M	$-136.67M	$-130.93M	$-95.82M	$-53.58M	—
Operating Cash Flow (USD)	$-103.88M	$-110.14M	$-88.35M	$14.05M	$-89.00M	$-41.27M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Century Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare IPSC with peers